PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLovastatin
Lovastatin
Altoprev, Lovastatin (lovastatin) is a small molecule pharmaceutical. Lovastatin was first approved as Mevacor on 1987-08-31. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against 3-hydroxy-3-methylglutaryl-Coenzyme A reductase. In addition, it is known to target nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Lovastatin (discontinued: Altoprev, Lovastatin, Mevacor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lovastatin
Tradename
Company
Number
Date
Products
ALTOPREVCovis PharmaN-021316 DISCN2002-06-26
4 products, RLD
MEVACORMerck & CoN-019643 DISCN1987-08-31
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
advicorNew Drug Application2012-10-04
altoprevNew Drug Application2024-12-31
lovastatinANDA2025-08-26
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C10: Lipid modifying agents
C10A: Lipid modifying agents, plain
C10AA: Hmg coa reductase inhibitors, plain lipid modifying drugs
C10AA02: Lovastatin
C10B: Lipid modifying agents, combinations
C10BA: Combinations of various lipid modifying agents
C10BA01: Lovastatin and nicotinic acid
HCPCS
No data
Clinical
Clinical Trials
622 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD00693745582721115
DyslipidemiasD050171432510749
Healthy volunteers/patients3314341
Cardiovascular diseasesD002318EFO_0000319I98215111139
Type 2 diabetes mellitusD003924EFO_0001360E11101109535
Coronary diseaseD00332711512432
Diabetes mellitusD003920EFO_0000400E08-E1324109731
HyperlipidemiasD006949EFO_0003774E78.511158630
AtherosclerosisD050197EFO_0003914I25.113810829
Coronary artery diseaseD003324I25.111912628
Show 105 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5021113
Prostatic neoplasmsD011471C611438
NeoplasmsD009369C805228
Multiple myelomaD009101C90.02416
Plasma cell neoplasmsD0542192416
Lung neoplasmsD008175C34.9055
Small cell lung carcinomaD05575244
Pancreatic neoplasmsD010190EFO_0003860C25234
Neurofibromatosis 1D009456Q85.011214
NeurofibromatosesD017253Q85.001214
Show 86 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2033
Acute kidney injuryD058186N17123
EpilepsyD004827EFO_0000474G40.9112
LymphomaD008223C85.911
Neurotoxicity syndromesD020258G9211
LipodystrophyD008060E88.111
Hiv seronegativityD01802311
Hepatitis bD00650911
Chronic hepatitis bD019694EFO_0004239B18.111
Renal cell carcinomaD002292EFO_000037611
Show 27 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyalgiaD063806M79.122
Congenital heart defectsD006330Q24.922
Heart valve diseasesD006349EFO_0009551I0822
Wounds and injuriesD014947T14.822
Chest painD002637R07.911
Liver diseasesD008107EFO_0001421K70-K7711
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
CytokinesisD04874911
Thyroid neoplasmsD013964EFO_000384111
Anaplastic thyroid carcinomaD06564611
Show 25 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLovastatin
INNlovastatin
Description
Lovastatin is a fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). It has a role as an Aspergillus metabolite, a prodrug, an anticholesteremic drug and an antineoplastic agent. It is a polyketide, a statin (naturally occurring), a member of hexahydronaphthalenes, a delta-lactone and a fatty acid ester. It is functionally related to a (S)-2-methylbutyric acid and a mevastatin.
Classification
Small molecule
Drug classenzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
Identifiers
PDB
CAS-ID75330-75-5
RxCUI
ChEMBL IDCHEMBL503
ChEBI ID40303
PubChem CID53232
DrugBankDB00227
UNII ID9LHU78OQFD (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ITGAL
ITGAL
Organism
Homo sapiens
Gene name
ITGAL
Gene synonyms
CD11A
NCBI Gene ID
Protein name
integrin alpha-L
Protein synonyms
antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide, CD11 antigen-like family member A, CD11a, integrin gene promoter, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide), Leukocyte adhesion glycoprotein LFA-1 alpha chain, Leukocyte function-associated molecule 1 alpha chain, LFA-1 alpha, LFA-1A, lymphocyte function-associated antigen 1, alpha polypeptide
Uniprot ID
Mouse ortholog
Itgal (16408)
integrin alpha-L (Q3U159)
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Lovastatin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Lovastatin
+
Niacin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 20,089 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,810 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use